サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1178226

モノクローナル抗体探索・分析の世界市場の分析 (2022年～2032年)

Monoclonal Antibody Discovery and Analysis Market Report 2022-2032
出版日: | 発行: Visiongain Reports Ltd. | ページ情報: 英文 437 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=199.66円

ご注意:
Single UserとTeamライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

モノクローナル抗体探索・分析の世界市場の分析 (2022年～2032年)
出版日: 2022年12月16日
発行: Visiongain Reports Ltd.
ページ情報: 英文 437 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のモノクローナル抗体探索・分析の市場規模は、2022年に56億1,000万米ドルを超過し、2032年まで9.0%のCAGRで成長すると予測されています。

当レポートでは、世界のモノクローナル抗体探索・分析の市場について分析し、技術の概要や市場の基本構造・最新情勢、主な促進・抑制要因、市場規模の推定値・予測値 (2022年～2032年)、業種別・用途別・プラットフォーム別・種類別および地域別・主要国の詳細動向、主要企業のプロファイル、COVID-19の影響と回復シナリオ、といった情報を取りまとめてお届けいたします。

目次

第1章 レポートの概要

第2章 エグゼクティブサマリー

第3章 市場概要

  • 主な分析結果
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 市場機会
  • サプライチェーン
  • コールドチェーン
  • 最近の動向・展開
  • 新型コロナウイルス感染症 (COVID-19) の影響分析
  • ポーターのファイブフォース分析

第4章 モノクローナル抗体探索・分析市場の分析：業種別

  • 主な分析結果
  • 市場魅力指数：業種別
  • 市場規模：業種別 (単位：100万米ドル、2022年～2032年)
  • 市場規模：地域別 (単位：100万米ドル、2022年～2032年)
  • 装置製造
  • サービス・ソリューション
  • 補助キット

第5章 モノクローナル抗体探索・分析市場の分析：用途別

  • 主な分析結果
  • 市場魅力指数：用途別
  • 市場規模：用途別 (単位：100万米ドル、2022年～2032年)
  • 市場規模：地域別 (単位：100万米ドル、2022年～2032年)
  • 治療用抗体の発見
    • 抗体発見のためのトランスジェニック動物プラットフォームを活用したトランスジェニック動物
    • サロゲート抗体
    • 医薬品開発
    • CAR-T抗体開発
  • 重要な試薬抗体の発見
    • 抗イディオタイプ抗体
    • 免疫原性・ADA向け試薬・試験
    • PK/PD/ADA向け抗体・アッセイ
    • 効能に関する研究
  • バイオマーカーと診断用抗体の探索
  • 研究用抗体の探索

第6章 モノクローナル抗体探索・分析市場の分析：プラットフォーム別

  • 主な分析結果
  • 市場魅力指数：プラットフォーム別
  • 市場規模：プラットフォーム別 (単位：100万米ドル、2022年～2032年)
  • 市場規模：地域別 (単位：100万米ドル、2022年～2032年)
  • ハイブリドーマ
  • 人間化
  • ファージディスプレイ
  • 酵母ディスプレイ
  • トランスジェニックマウス

第7章 モノクローナル抗体探索・分析市場の分析：種類別

  • 主な分析結果
  • 市場魅力指数：種類別
  • 市場規模：種類別 (単位：100万米ドル、2022年～2032年)
  • 市場規模：地域別 (単位：100万米ドル、2022年～2032年)
  • 抗原の開発
  • モノクローナル抗体の探索
  • モノクローナル抗体の製造
  • ポリクローナル抗体
  • ラベルフリー・カイネティクス分析
  • 細胞バンク

第8章 モノクローナル抗体探索・分析市場の分析：地域別

  • 主な分析結果
  • 市場魅力指数：地域別
  • 市場予測 (単位：100万米ドル、2022年～2032年)
  • モノクローナル抗体探索・分析市場：地域別
  • モノクローナル抗体探索・分析市場：業種別
  • モノクローナル抗体探索・分析市場：用途別
  • モノクローナル抗体探索・分析市場：プラットフォーム別
  • モノクローナル抗体探索・分析市場：種類別

第9章 北米のモノクローナル抗体探索・分析市場の分析

  • 主な分析結果
  • 北米のモノクローナル抗体探索・分析市場：魅力指数
  • 北米のモノクローナル抗体探索・分析の市場規模 (単位：100万米ドル、2022年～2032年)
  • 市場規模の推定・予測：国別
  • 市場規模の推計・予測：業種別
  • 市場規模の推計・予測：用途別
  • 市場規模の推定・予測：プラットフォーム別
  • 市場規模の推定・予測：種類別
  • 米国市場の分析
  • カナダ市場の分析

第10章 欧州のモノクローナル抗体探索・分析市場の分析

  • 主な分析結果
  • 欧州のモノクローナル抗体探索・分析市場：魅力指数
  • 欧州のモノクローナル抗体探索・分析の市場規模 (単位：100万米ドル、2022年～2032年)
  • 市場規模の推定・予測：国別
  • 市場規模の推計・予測：業種別
  • 市場規模の推計・予測：用途別
  • 市場規模の推定・予測：プラットフォーム別
  • 市場規模の推定・予測：種類別
  • ドイツ市場の分析
  • 英国市場の分析
  • フランス市場の分析
  • イタリア市場の分析
  • スペイン市場の分析
  • 他の欧州諸国の市場の分析

第11章 アジア太平洋のモノクローナル抗体探索・分析市場の分析

  • 主な分析結果
  • アジア太平洋のモノクローナル抗体探索・分析市場：魅力指数
  • アジア太平洋のモノクローナル抗体探索・分析の市場規模 (単位：100万米ドル、2022年～2032年)
  • 市場規模の推定・予測：国別
  • 市場規模の推計・予測：業種別
  • 市場規模の推計・予測：用途別
  • 市場規模の推定・予測：プラットフォーム別
  • 市場規模の推定・予測：種類別
  • 中国市場の分析
  • インド市場の分析
  • 日本市場の分析
  • 韓国市場の分析
  • オーストラリア市場の分析
  • 他のアジア太平洋諸国の市場の分析

第12章 中東・アフリカのモノクローナル抗体探索・分析市場の分析

  • 主な分析結果
  • 中東・アフリカのモノクローナル抗体探索・分析市場：魅力指数
  • 中東・アフリカのモノクローナル抗体探索・分析の市場規模 (単位：100万米ドル、2022年～2032年)
  • 市場規模の推定・予測：国別
  • 市場規模の推計・予測：業種別
  • 市場規模の推計・予測：用途別
  • 市場規模の推定・予測：プラットフォーム別
  • 市場規模の推定・予測：種類別
  • 南アフリカ市場の分析
  • サウジアラビア市場の分析
  • トルコ市場の分析
  • 他の中東・アフリカ諸国の市場の分析

第13章 ラテンアメリカのモノクローナル抗体探索・分析市場の分析

  • 主な分析結果
  • ラテンアメリカのモノクローナル抗体探索・分析市場：魅力指数
  • ラテンアメリカのモノクローナル抗体探索・分析の市場規模 (単位：100万米ドル、2022年～2032年)
  • 市場規模の推定・予測：国別
  • 市場規模の推計・予測：業種別
  • 市場規模の推計・予測：用途別
  • 市場規模の推定・予測：プラットフォーム別
  • 市場規模の推定・予測：種類別
  • ブラジル市場の分析
  • メキシコ市場の分析
  • 他のラテンアメリカ諸国の市場の分析

第14章 競合情勢

  • 企業シェア分析
  • 主要なビジネス戦略の分析：買収
  • 主要なビジネス戦略の分析：合意
  • 主要なビジネス戦略の分析：アライアンス
  • 主要なビジネス戦略の分析：コラボレーション
  • 主要なビジネス戦略の分析：拡張
  • 主要なビジネス戦略の分析：ジョイントベンチャー
  • 主要なビジネス戦略の分析：新製品の発売
  • 主要なビジネス戦略の分析：パートナーシップ

第15章 企業プロファイル

  • AbbVie Inc.
  • Amgen Inc.
  • Amneal Pharmaceutical LLC
  • AstraZeneca
  • Bayer AG
  • BIOGEN
  • Bristol-Myers Squibb company
  • Eisai Co.Ltd
  • Eli Lilly and Company
  • F. Hoffman-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson &Johnson Ltd
  • Lupin Limited
  • Viatris Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Limited

第16章 結論と提言

図表

List of Tables

  • Table 1 Monoclonal Antibody Discovery & Analysis Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
  • Table 2 Monoclonal Antibody Discovery & Analysis Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%)) (V-Shaped Recovery Scenario)
  • Table 3 Monoclonal Antibody Discovery & Analysis Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%)) (V-Shaped Recovery Scenario)
  • Table 4 Monoclonal Antibody Discovery & Analysis Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%)) (W-Shaped Recovery Scenario)
  • Table 5 Monoclonal Antibody Discovery & Analysis Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%)) (W-Shaped Recovery Scenario)
  • Table 6 Monoclonal Antibody Discovery & Analysis Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%)) (U-Shaped Recovery Scenario)
  • Table 7 Monoclonal Antibody Discovery & Analysis Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%)) (U-Shaped Recovery Scenario)
  • Table 8 Monoclonal Antibody Discovery & Analysis Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%)) (L-Shaped Recovery Scenario)
  • Table 9 Monoclonal Antibody Discovery & Analysis Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%)) (L-Shaped Recovery Scenario)
  • Table 10 Monoclonal Antibody Discovery & Analysis Market by Business Type, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 11 Global Instruments Manufacturing Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 12 Global Instruments Manufacturing Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 13 Global Services & Solutions Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 14 Global Services & Solutions Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 15 Global Ancillary Kits Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 16 Global Ancillary Kits Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 17 Monoclonal Antibody Discovery & Analysis Market by Application, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 18 Global Therapeutic Antibody Discovery Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 19 Global Therapeutic Antibody Discovery Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 20 Global Critical Reagent Antibody Discovery Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 21 Global Critical Reagent Antibody Discovery Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 22 Global Biomarker and Diagnostic Antibody Discovery Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 23 Global Biomarker and Diagnostic Antibody Discovery Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 24 Global Research Antibody Discovery Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 25 Global Research Antibody Discovery Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 26 Monoclonal Antibody Discovery & Analysis Market by Platform, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 27 Global Hybridoma Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 28 Global Hybridoma Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 29 Global Humanization Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 30 Global Humanization Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 31 Global Phage Display Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 32 Global Phage Display Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 33 Global Yeast Display Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 34 Global Yeast Display Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 35 Global Transgenic Rodents Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 36 Global Transgenic Rodents Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 37 Monoclonal Antibody Discovery & Analysis Market by Type, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 38 Global Antigen Development Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 39 Global Antigen Development Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 40 Global Monoclonal Antibody Discovery Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 41 Global Monoclonal Antibody Discovery Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 42 Global Monoclonal Antibody Manufacturing Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 43 Global Monoclonal Antibody Manufacturing Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 44 Global Polyclonal Antibodies Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 45 Global Polyclonal Antibodies Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 46 Global Label-free Kinetics Analysis Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 47 Global Label-free Kinetics Analysis Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 48 Global Cell Banking Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 49 Global Cell Banking Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 50 Monoclonal Antibody Discovery & Analysis Market Forecast, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 51 Monoclonal Antibody Discovery & Analysis Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 52 Monoclonal Antibody Discovery & Analysis Market by Business Type, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 53 Monoclonal Antibody Discovery & Analysis Market by Application, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 54 Monoclonal Antibody Discovery & Analysis Market by Platform, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 55 Monoclonal Antibody Discovery & Analysis Market by Type, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 56 North America Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 57 North America Monoclonal Antibody Discovery & Analysis Market by Country, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 58 North America Monoclonal Antibody Discovery & Analysis Market by Business Type, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 59 North America Monoclonal Antibody Discovery & Analysis Market by Application, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 60 North America Monoclonal Antibody Discovery & Analysis Market by Platform, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 61 North America Monoclonal Antibody Discovery & Analysis Market by Type, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 62 U.S. Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 63 Canada Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 64 Europe Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 65 Europe Monoclonal Antibody Discovery & Analysis Market by Country, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 66 Europe Monoclonal Antibody Discovery & Analysis Market by Business Type, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 67 Europe Monoclonal Antibody Discovery & Analysis Market by Application, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 68 Europe Monoclonal Antibody Discovery & Analysis Market by Platform, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 69 Europe Monoclonal Antibody Discovery & Analysis Market by Type, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 70 Germany Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 71 UK Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 72 France Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 73 Italy Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 74 Spain Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 75 Rest of Europe Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 76 Asia-Pacific Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 77 Asia-Pacific Monoclonal Antibody Discovery & Analysis Market by Country, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 78 Asia-Pacific Monoclonal Antibody Discovery & Analysis Market by Business Type, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 79 Asia-Pacific Monoclonal Antibody Discovery & Analysis Market by Application, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 80 Asia-Pacific Monoclonal Antibody Discovery & Analysis Market by Platform, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 81 Asia-Pacific Monoclonal Antibody Discovery & Analysis Market by Type, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 82 China Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 83 India Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 84 Japan Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 85 South Korea Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 86 Australia Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 87 Rest of Asia-Pacific Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 88 Middle East & Africa Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 89 Middle East & Africa Monoclonal Antibody Discovery & Analysis Market by Country, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 90 Middle East & Africa Monoclonal Antibody Discovery & Analysis Market by Business Type, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 91 Middle East & Africa Monoclonal Antibody Discovery & Analysis Market by Application, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 92 Middle East & Africa Monoclonal Antibody Discovery & Analysis Market by Platform, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 93 Middle East & Africa Monoclonal Antibody Discovery & Analysis Market by Type, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 94 South Africa Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 95 Saudi Arabia Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 96 Turkey Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 97 Rest of Middle East & Africa Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 98 Latin America Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 99 Latin America Monoclonal Antibody Discovery & Analysis Market by Country, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 100 Latin America Monoclonal Antibody Discovery & Analysis Market by Business Type, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 101 Latin America Monoclonal Antibody Discovery & Analysis Market by Application, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 102 Latin America Monoclonal Antibody Discovery & Analysis Market by Platform, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 103 Latin America Monoclonal Antibody Discovery & Analysis Market by Type, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 104 Brazil Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 105 Mexico Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 106 Rest of Latin America Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%), CAGR (%))
  • Table 107 Key Business Strategies Adopted by Key Players in Monoclonal Antibody Discovery & Analysis Market
  • Table 108 Key Business Strategies Adopted by Key Players in Monoclonal Antibody Discovery & Analysis Market
  • Table 109 Key Business Strategies Adopted by Key Players in Monoclonal Antibody Discovery & Analysis Market
  • Table 110 Key Business Strategies Adopted by Key Players in Monoclonal Antibody Discovery & Analysis Market
  • Table 111 Key Business Strategies Adopted by Key Players in Monoclonal Antibody Discovery & Analysis Market
  • Table 112 Key Business Strategies Adopted by Key Players in Monoclonal Antibody Discovery & Analysis Market
  • Table 113 Key Business Strategies Adopted by Key Players in Monoclonal Antibody Discovery & Analysis Market
  • Table 114 Key Business Strategies Adopted by Key Players in Monoclonal Antibody Discovery & Analysis Market
  • Table 115 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 116 AbbVie Inc.: Product Benchmarking
  • Table 117 AbbVie Inc.: Strategic Outlook
  • Table 118 Amgen Inc: Key Details (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 119 Amgen Inc.: Product Benchmarking
  • Table 120 Amgen Inc.: Strategic Outlook
  • Table 121 Amneal Pharmaceutical LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 122 Amneal Pharmaceutical LLC: Strategic Outlook
  • Table 123 Astrazeneca: Key Details (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 124 Astrazeneca.: Product Benchmarking
  • Table 125 Astrazeneca: Strategic Outlook
  • Table 126 Bayer AG: Key Details (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 127 Bayer AG: Strategic Outlook
  • Table 128 BIOGEN: Key Details (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 129 BIOGEN: Product Benchmarking
  • Table 130 BIOGEN: Strategic Outlook
  • Table 131 Bristol-Myers Squibb Company: Key Details (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 132 Bristol-Myers Squibb company.: Product Benchmarking
  • Table 133 Bristol-Myers Squibb Company: Strategic Outlook
  • Table 134 Eisai Co. Ltd: Key Details (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 135 Eisai Co.Ltd: Product Benchmarking
  • Table 136 Eisai Co.Ltd: Strategic Outlook
  • Table 137 Eli Lilly and Company: Key Details (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 138 Eli-Lily & Company: Product Benchmarking
  • Table 139 Eli-Lily & Company: Strategic Outlook
  • Table 140 F. Hoffman-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 141 F. Hoffman-La Roche Ltd.: Product Benchmarking
  • Table 142 F. Hoffman-La Roche Ltd: Strategic Outlook
  • Table 143 GlaxoSmithKline plc .: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 144 GlaxoSmithKline plc: Product Benchmarking
  • Table 145 GlaxoSmithKline plc: Strategic Outlook
  • Table 146 Johnson & Johnson Ltd: Key Details (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 147 Johnson & Johnson Ltd: Strategic Outlook
  • Table 148 Lupin Limited.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 149 Lupin.: Product Benchmarking
  • Table 150 Lupin: Strategic Outlook
  • Table 151 Viatris Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 152 Viatris Inc.: Product Benchmarking
  • Table 153 Viatris Inc..: Strategic Outlook
  • Table 154 Novartis AG.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 155 Novartis AG.: Product Benchmarking
  • Table 156 Novartis AG.: Strategic Outlook
  • Table 157 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 158 Pfizer Inc.: Strategic Outlook
  • Table 159 Regeneron Pharmaceuticals Inc: Key Details (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 160 Regeneron Pharmaceutical Inc: Product Benchmarking
  • Table 161 Regeneron Pharmaceutical Inc: Strategic Outlook
  • Table 162 Sanofi S.A.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 163 Sanofi S.A.: Product Benchmarking
  • Table 164 Sanofi S.A.: Strategic Outlook
  • Table 165 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 166 Teva Pharmaceutical Industries Ltd.: Strategic Outlook
  • Table 167 Zydus Lifesciences Limited: Key Details (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 168 Zydus Lifesciences Limited: Product Benchmarking

List of Figures

  • Figure 1 Monoclonal Antibody Discovery & Analysis Market Segmentation
  • Figure 2 Monoclonal Antibody Discovery & Analysis Market Forecast by Region: Market Attractiveness Index
  • Figure 3 Monoclonal Antibody Discovery & Analysis Market by Application Method: Market Attractiveness Index
  • Figure 4 Monoclonal Antibody Discovery & Analysis Market by Business type: Market Attractiveness Index
  • Figure 5 Monoclonal Antibody Discovery & Analysis Market by Platform: Market Attractiveness Index
  • Figure 6 Monoclonal Antibody Discovery & Analysis Market by Type: Market Attractiveness Index
  • Figure 7 Monoclonal Antibody Discovery & Analysis Market: Market Dynamics
  • Figure 8 Primary indications for antibody therapeutics approved or in regulatory review in the United States or European Union
  • Figure 9 Targets for antibody therapeutics approved or in regulatory review in the United States or European Union for cancer.
  • Figure 10 Targets for antibody therapeutics approved or in regulatory review in the United States or European Union for noncancer indications.
  • Figure 11 Global COVID Impact Analysis: Monoclonal Antibody Discovery & Analysis Market Recovery Scenarios
  • Figure 12 Monoclonal Antibody Discovery & Analysis Market Forecast, 2022-2032 (US$ mn, AGR (%)) (V-Shaped Recovery Scenario)
  • Figure 13 Monoclonal Antibody Discovery & Analysis Market by Region, 2022-2032 (US$ mn, AGR (%)) (V-Shaped Recovery Scenario)
  • Figure 14 Monoclonal Antibody Discovery & Analysis Market Forecast, 2022-2032 (US$ mn, AGR (%))(W-Shaped Recovery Scenario)
  • Figure 15 Monoclonal Antibody Discovery & Analysis Market by Region, 2022-2032 (US$ mn, AGR (%)) (W-Shaped Recovery Scenario)
  • Figure 16 Monoclonal Antibody Discovery & Analysis Market Forecast, 2022-2032 (US$ mn, AGR (%)) (U-Shaped Recovery Scenario)
  • Figure 17 Monoclonal Antibody Discovery & Analysis Market by Region, 2022-2032 (US$ mn, AGR (%)) (U-Shaped Recovery Scenario)
  • Figure 18 Monoclonal Antibody Discovery & Analysis Market Forecast, 2022-2032 (US$ mn, AGR (%)) (L-Shaped Recovery Scenario)
  • Figure 19 Monoclonal Antibody Discovery & Analysis Market by Region, 2022-2032 (US$ mn, AGR (%)) (L-Shaped Recovery Scenario)
  • Figure 20 Monoclonal Antibody Discovery & Analysis Market: Porter's Five Forces Analysis
  • Figure 21 Business Type Method Monoclonal Antibodies Market Attractiveness Index
  • Figure 22 Monoclonal Antibody Discovery & Analysis Market by Business Type, 2022-2032 (US$ mn, AGR (%))
  • Figure 23 Global Instruments Manufacturing Market by Region, 2022-2032 (US$ mn, AGR (%))
  • Figure 24 Global Instruments Manufacturing Market Forecast, 2022-2032 (US$ mn, AGR (%))
  • Figure 25 Global Services & Solutions Market Forecast, 2022-2032 (US$ mn, AGR (%))
  • Figure 26 Global Services & Solutions Market by Region, 2022-2032 (US$ mn, AGR (%))
  • Figure 27 Global Ancillary Kits Market Forecast, 2022-2032 (US$ mn, AGR (%))
  • Figure 28 Global Ancillary Kits Market by Region, 2022-2032 (US$ mn, AGR (%))
  • Figure 29 Application Segment Market Attractiveness Index
  • Figure 30 Monoclonal Antibody Discovery & Analysis Market by Application, 2022-2032 (US$ mn, AGR (%))
  • Figure 31 Global Therapeutic Antibody Discovery Market by Region, 2022-2032 (US$ mn, AGR (%))
  • Figure 32 Antibodies
  • Figure 33 CAR-Ts are produced using antibodies
  • Figure 34 Global Therapeutic Antibody Discovery Market Forecast, 2022-2032 (US$ mn, AGR (%))
  • Figure 35 Ab Structure
  • Figure 36 Immunogenicity Risk of Therapeutic Antibodies
  • Figure 37 Global Critical Reagent Antibody Discovery Market Forecast, 2022-2032 (US$ mn, AGR (%))
  • Figure 38 Global Critical Reagent Antibody Discovery Market by Region, 2022-2032 (US$ mn, AGR (%))
  • Figure 39 Global Biomarker and Diagnostic Antibody Discovery Market Forecast, 2022-2032 (US$ mn, AGR (%))
  • Figure 40 Global Biomarker and Diagnostic Antibody Discovery Market by Region, 2022-2032 (US$ mn, AGR (%))
  • Figure 41 Global Research Antibody Discovery Market Forecast, 2022-2032 (US$ mn, AGR (%))
  • Figure 42 Global Research Antibody Discovery Market by Region, 2022-2032 (US$ mn, AGR (%))
  • Figure 43 Platform Segment Market Attractiveness Index
  • Figure 44 Monoclonal Antibody Discovery & Analysis Market by Platform, 2022-2032 (US$ mn, AGR (%))
  • Figure 45 Global Hybridoma Market by Region, 2022-2032 (US$ mn, AGR (%))
  • Figure 46 Global Hybridoma Market Forecast, 2022-2032 (US$ mn, AGR (%))
  • Figure 47 Global Humanization Market Forecast, 2022-2032 (US$ mn, AGR (%))
  • Figure 48 Global Humanization Market by Region, 2022-2032 (US$ mn, AGR (%))
  • Figure 49 Global Phage Display Market Forecast, 2022-2032 (US$ mn, AGR (%))
  • Figure 50 Global Phage Display Market by Region, 2022-2032 (US$ mn, AGR (%))
  • Figure 51 Global Yeast Display Market Forecast, 2022-2032 (US$ mn, AGR (%))
  • Figure 52 Global Yeast Display Market by Region, 2022-2032 (US$ mn, AGR (%))
  • Figure 53 Global Transgenic Rodents Market Forecast, 2022-2032 (US$ mn, AGR (%))
  • Figure 54 Global Transgenic Rodents Market by Region, 2022-2032 (US$ mn, AGR (%))
  • Figure 55 Monoclonal Antibody Discovery & Analysis Market Forecast by Type 2022, 2032 (Revenue, CAGR (%))
  • Figure 56 Type Segment Market Attractiveness Index
  • Figure 57 Monoclonal Antibody Discovery & Analysis Market by Type, 2022-2032 (US$ mn, AGR (%))
  • Figure 58 Global Antigen Development Market by Region, 2022-2032 (US$ mn, AGR (%))
  • Figure 59 Global Antigen Development Market Forecast, 2022-2032 (US$ mn, AGR (%))
  • Figure 60 Global Monoclonal Antibody Discovery Market Forecast, 2022-2032 (US$ mn, AGR (%))
  • Figure 61 Global Monoclonal Antibody Discovery Market by Region, 2022-2032 (US$ mn, AGR (%))
  • Figure 62 Global Monoclonal Antibody Manufacturing Market Forecast, 2022-2032 (US$ mn, AGR (%))
  • Figure 63 Global Monoclonal Antibody Manufacturing Market by Region, 2022-2032 (US$ mn, AGR (%))
  • Figure 64 Global Polyclonal Antibodies Market Forecast, 2022-2032 (US$ mn, AGR (%))
  • Figure 65 Global Polyclonal Antibodies Market by Region, 2022-2032 (US$ mn, AGR (%))
  • Figure 66 Global Label-free Kinetics Analysis Market Forecast, 2022-2032 (US$ mn, AGR (%))
  • Figure 67 Global Label-free Kinetics Analysis Market by Region, 2022-2032 (US$ mn, AGR (%))
  • Figure 68 Global Cell Banking Market Forecast, 2022-2032 (US$ mn, AGR (%))
  • Figure 69 Global Cell Banking Market by Region, 2022-2032 (US$ mn, AGR (%))
  • Figure 70 Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
  • Figure 71 Monoclonal Antibody Discovery & Analysis Market Forecast, 2022-2032 (US$ mn, AGR (%))
  • Figure 72 Monoclonal Antibody Discovery & Analysis Market by Region, 2022-2032 (US$ mn, AGR (%))
  • Figure 73 Monoclonal Antibody Discovery & Analysis Market by Business Type, 2022-2032 (US$ mn, AGR (%))
  • Figure 74 Monoclonal Antibody Discovery & Analysis Market by Application, 2022-2032 (US$ mn, AGR (%))
  • Figure 75 Monoclonal Antibody Discovery & Analysis Market by Platform, 2022-2032 (US$ mn, AGR (%))
  • Figure 76 Monoclonal Antibody Discovery & Analysis Market by Type, 2022-2032 (US$ mn, AGR (%))
  • Figure 77 North America Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
  • Figure 78 North America Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 79 North America Monoclonal Antibody Discovery & Analysis Market by Country, 2022-2032 (US$ mn, AGR (%))
  • Figure 80 North America Monoclonal Antibody Discovery & Analysis Market by Business Type, 2022-2032 (US$ mn, AGR (%))
  • Figure 81 North America Monoclonal Antibody Discovery & Analysis Market by Application, 2022-2032 (US$ mn, AGR (%))
  • Figure 82 North America Monoclonal Antibody Discovery & Analysis Market by Platform, 2022-2032 (US$ mn, AGR (%))
  • Figure 83 North America Monoclonal Antibody Discovery & Analysis Market by Type, 2022-2032 (US$ mn, AGR (%))
  • Figure 84 U.S. Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 85 Canada Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 86 South America Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
  • Figure 87 Europe Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 88 Europe Monoclonal Antibody Discovery & Analysis Market by Country, 2022-2032 (US$ mn, AGR (%))
  • Figure 89 Europe Monoclonal Antibody Discovery & Analysis Market by Business Type, 2022-2032 (US$ mn, AGR (%))
  • Figure 90 Europe Monoclonal Antibody Discovery & Analysis Market by Application, 2022-2032 (US$ mn, AGR (%))
  • Figure 91 Europe Monoclonal Antibody Discovery & Analysis Market by Platform, 2022-2032 (US$ mn, AGR (%))
  • Figure 92 Europe Monoclonal Antibody Discovery & Analysis Market by Type, 2022-2032 (US$ mn, AGR (%))
  • Figure 93 Germany Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 94 UK Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 95 France Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 96 Italy Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 97 Spain Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 98 Rest of Europe Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 99 Asia-Pacific Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
  • Figure 100 Asia-Pacific Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 101 Asia-Pacific Monoclonal Antibody Discovery & Analysis Market by Country, 2022-2032 (US$ mn, AGR (%))
  • Figure 102 Asia-Pacific Monoclonal Antibody Discovery & Analysis Market by Business Type, 2022-2032 (US$ mn, AGR (%))
  • Figure 103 Asia-Pacific Monoclonal Antibody Discovery & Analysis Market by Application, 2022-2032 (US$ mn, AGR (%))
  • Figure 104 Asia-Pacific Monoclonal Antibody Discovery & Analysis Market by Platform, 2022-2032 (US$ mn, AGR (%))
  • Figure 105 Asia-Pacific Monoclonal Antibody Discovery & Analysis Market by Type, 2022-2032 (US$ mn, AGR (%))
  • Figure 106 China Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 107 India Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 108 Japan Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 109 South Korea Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 110 Australia Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 111 Rest of Asia-Pacific Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 112 Middle East and Africa Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
  • Figure 113 Middle East & Africa Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 114 Middle East & Africa Monoclonal Antibody Discovery & Analysis Market by Country, 2022-2032 (US$ mn, AGR (%))
  • Figure 115 Middle East & Africa Monoclonal Antibody Discovery & Analysis Market by Business Type, 2022-2032 (US$ mn, AGR (%))
  • Figure 116 Middle East & Africa Monoclonal Antibody Discovery & Analysis Market by Application, 2022-2032 (US$ mn, AGR (%))
  • Figure 117 Middle East & Africa Monoclonal Antibody Discovery & Analysis Market by Platform, 2022-2032 (US$ mn, AGR (%))
  • Figure 118 Middle East & Africa Monoclonal Antibody Discovery & Analysis Market by Type, 2022-2032 (US$ mn, AGR (%))
  • Figure 119 South Africa Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 120 Saudi Arabia Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 121 Turkey Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 122 Rest of Middle East & Africa Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 123 Latin America Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
  • Figure 124 Latin America Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 125 Latin America Monoclonal Antibody Discovery & Analysis Market by Country, 2022-2032 (US$ mn, AGR (%))
  • Figure 126 Latin America Monoclonal Antibody Discovery & Analysis Market by Business Type, 2022-2032 (US$ mn, AGR (%))
  • Figure 127 Latin America Monoclonal Antibody Discovery & Analysis Market by Application, 2022-2032 (US$ mn, AGR (%))
  • Figure 128 Latin America Monoclonal Antibody Discovery & Analysis Market by Platform, 2022-2032 (US$ mn, AGR (%))
  • Figure 129 Latin America Monoclonal Antibody Discovery & Analysis Market by Type, 2022-2032 (US$ mn, AGR (%))
  • Figure 130 Brazil Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 131 Mexico Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 132 Rest of Latin America Monoclonal Antibody Discovery & Analysis Market by Value, 2022-2032 (US$ mn, AGR (%))
  • Figure 133 Monoclonal Antibody Discovery & Analysis Market: Company Share Analysis, 2021
  • Figure 134 AbbVie Inc.: Net Revenue, 2017-2021 (US$ million, AGR (%))
  • Figure 135 AbbVie Inc.: Gross Profit, 2017-2021 (US$ million, AGR (%))
  • Figure 136 AbbVie Inc.: R&D Expenses, 2017-2021 (US$ million, AGR (%))
  • Figure 138 Amgen Inc.: Net Revenue, 2017-2021 (US$ million, AGR (%))
  • Figure 139 Amgen Inc: Gross Profit, 2017-2021 (US$ million, AGR (%))
  • Figure 140 Amgen Inc. R&D Expenses, 2017-2021 (US$ million, AGR (%))
  • Figure 141 Amneal Pharmaceutical LLC: Net Revenue, 2017-2021 (US$ million, AGR (%))
  • Figure 142 Amneal Pharmaceutical LLC: R&D Expenses, 2017-2021 (US$ million, AGR (%))
  • Figure 143 Astrazeneca: Net Revenue, 2017-2021 (US$ million, AGR (%))
  • Figure 144 Astrazeneca: R&D Expenses, 2017-2021 (US$ million, AGR (%))
  • Figure 145 Astrazeneca: Regional Revenue Share, 2021 (%)
  • Figure 146 Bayer AG: Net Revenue, 2017-2021 (US$ million, AGR (%))
  • Figure 147 Bayer AG: R&D Expenses, 2017-2021 (US$ million, AGR (%))
  • Figure 148 Bayer AG Company: Regional Revenue Share, 2021 (%)
  • Figure 149 BIOGEN: Net Revenue, 2017-2021 (US$ million, AGR (%))
  • Figure 150 BIOGEN R&D Expenses, 2017-2021 (US$ million, AGR (%))
  • Figure 151 BIOGEN: Regional Revenue Share, 2021 (%)
  • Figure 152 Bristol-Myers Squibb Company: Net Revenue, 2017-2021 (US$ million, AGR (%))
  • Figure 153 Bristol-Myers Squibb Company: R&D Expenses, 2017-2021 (US$ million, AGR (%)
  • Figure 154 Bristol-Myers Squibb company: Regional Revenue Share, 2021 (%)
  • Figure 155 Eisai Co. Ltd: Net Revenue, 2017-2021 (US$ million, AGR (%))
  • Figure 156 Eisai Co.Ltd R&D Expenses, 2017-2021 (US$ million, AGR (%))
  • Figure 157 Eli-Lily & Company: Net Revenue, 2017-2021 (US$ million, AGR (%))
  • Figure 158 Eli-Lily & Company: R&D Expenses, 2017-2021 (US$ million, AGR (%))
  • Figure 159 Eli-Lily & Company Regional Revenue Share, 2021 (%)
  • Figure 160 F. Hoffman-La Roche Ltd.: Net Revenue, 2017-2021 (US$ million, AGR (%))
  • Figure 161 F. Hoffman-La Roche Ltd.: R&D Expenses, 2017-2021 (US$ million, AGR (%))
  • Figure 162 F. Hoffman-La Roche Ltd.: Regional Revenue Share, 2021 (%)
  • Figure 163 GlaxoSmithKline plc: Net Revenue, 2018-2021 (US$ million, AGR (%))
  • Figure 164 GlaxoSmithKline plc: R&D Expenses, 2017-2021 (US$ million, AGR (%))
  • Figure 165 GlaxoSmithKline plc: Regional Revenue Share, 2021 (%)
  • Figure 166 Johnson & Johnson Ltd: Net Revenue, 2017-2021 (US$ million, AGR (%))
  • Figure 167 Johnson & Johnson Ltd: R&D Expenses, 2017-2021 (US$ million, AGR (%)
目次
Product Code: PHA1221

The global Monoclonal Antibody Discovery and Analysis market is projected to grow at a CAGR of 9.0% by 2032.

“The Monoclonal Antibody Discovery and Analysis Market Report 2022-2032”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Growing Demand for Monoclonal Antibodies for Cancer Treatments

Monoclonal antibodies have demonstrated anticancer efficacy in a variety of cancers, thus they are not necessary for cancer therapy. Most toxicities, including fever, nausea, fatigue, changes in blood pressure, and bronchospasm, are self-limiting. The efficacy and timeliness of antibody-based diagnostic tests for a variety of disorders have both been enhanced by monoclonal antibodies. Clinical studies for more than 250 therapeutic monoclonal antibodies are now being conducted. These antibodies are used to treat cancer, autoimmune disorders, infectious diseases, and transplant patients. Inadequate effector functions, immunogenicity, and problems with pharmacokinetics have all been addressed through chimerization and humanization. As of November 1, 2021, 11 antibody treatments had been given first clearance for usage in either the European Union or the United States: Therapeutic antibodies will unavoidably continue to be a key component of drug research for many years to come. Regardless of the particular path used to produce the next generation of monoclonal antibody therapies, this is true.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the monoclonal antibody discovery and analysis market evolving?
  • What is driving and restraining the monoclonal antibody discovery and analysis market?
  • How will each monoclonal antibody discovery and analysis submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
  • How will the market shares for each monoclonal antibody discovery and analysis submarket develop from 2022 to 2032?
  • What will be the main driver for the overall market from 2022 to 2032?
  • Will leading monoclonal antibody discovery and analysis markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the monoclonal antibody discovery and analysis projects for these leading companies?
  • How will the industry evolve during the period between 2020 and 2032? What are the implications of monoclonal antibody discovery and analysis projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the monoclonal antibody discovery and analysis market?
  • Where is the monoclonal antibody discovery and analysis market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the monoclonal antibody discovery and analysis market today, and over the next 10 years:

  • Our 437-page report provides 168 tables and 183 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the monoclonal antibody discovery and analysis market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising monoclonal antibody discovery and analysis prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Business Type

  • Instruments Manufacturing
  • Services & Solutions
  • Ancillary Kits

Application

  • Therapeutic Antibody Discovery
  • Critical Reagent Antibody Discovery
  • Biomarker and Diagnostic Antibody Discovery
  • Research Antibody Discovery

Platform

  • Hybridoma
  • Humanization
  • Phage Display
  • Yeast Display
  • Transgenic Rodents

Type

  • Antigen Development
  • Monoclonal Antibody Discovery
  • Monoclonal Antibody Manufacturing
  • Polyclonal Antibodies
  • Label-free Kinetics Analysis
  • Cell Banking

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20 leading national markets:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • Spain
  • United Kingdom
  • France
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Middle East & Africa

  • Turkey
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

The report also includes profiles and for some of the leading companies in the Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth

  • AbbVie Inc.
  • Amgen Inc.
  • Amneal Pharmaceutical LLC
  • AstraZeneca
  • Bayer AG
  • BIOGEN
  • Bristol- Myers Squibb company
  • Eisai Co. Ltd
  • Eli Lilly and Company
  • F. Hoffman-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson Ltd.
  • Lupin Limited
  • Viatris Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Limited

Overall world revenue for Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032 in terms of value the market will surpass US$5,610 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032 report help you?

In summary, our 430+ page report provides you with the following knowledge:

  • Revenue forecasts to 2032 for Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032 Market, with forecasts for business type, platform, type, application and company size, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2032 for four regional and 20 key national markets - See forecasts for the Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Middle East & Africa and Latin America. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 20 of the major companies involved in the Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Monoclonal Antibody Discovery & Analysis Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Reports
  • 1.10 About

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Launches of New Products
      • 3.2.1.2 Growing Funding and Healthcare Costs
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Price Limits
      • 3.2.2.2 Pressures for Regulatory Approval
      • 3.2.2.3 Induction of Biosimilars
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Pandemic Offered Opportunities
      • 3.2.3.2 Patent Exclusive Rights
  • 3.3 Supply Chain
    • 3.3.1 Immunotherapy Drug Supply Chain and Logistics Challenges
    • 3.3.2 Immunotherapies' Vulnerability
    • 3.3.3 A One-of-a-Kind Starting Point for T-Cell Treatments
    • 3.3.4 The Supply Chain's Missing Manufacturing Link
    • 3.3.5 Limited Availability
    • 3.3.6 Keeping Command of the Immunotherapy Supply Chain
  • 3.4 Cold chain
    • 3.4.1 Agencies Favor Transport Simulation
    • 3.4.2 Packaging Qualification for Thermal
    • 3.4.3 Requests for Information Regarding the Schedule of Verification Studies
  • 3.5 Recent Trends/ Developments
    • 3.5.1 The FDA Received an Investigational New Drug (IND) Application for VRDN-002
    • 3.5.2 Verseau Therapeutics, Inc. Reported on January 4, 2022, FDA Approval
    • 3.5.3 A Veterinary mAb Receives FDA Approval for the First Time
    • 3.5.4 Two Antibody Therapies Are in Seagen's Clinical Study Queue.
    • 3.5.5 Spirea Raises £2.4 Million to Create Cancer-Specific Antibody Drug Conjugates
    • 3.5.6 Exelixis, Inc. of California and BioInvent International AB of Swedenpartner to Create New Antibodies for Immuno-oncology Treatments
  • 3.6 COVID-19 Impact Analysis
  • 3.7 Porter's Five Forces Analysis
    • 3.7.1 Supplier Power
    • 3.7.2 Buyer Power
    • 3.7.3 Competitive Rivalry
    • 3.7.4 Threat from Substitutes
    • 3.7.5 Threat of New Entrants

4 Monoclonal Antibody Discovery & Analysis Market Analysis by Business Type

  • 4.1 Key Findings
  • 4.2 Business Type Segment: Market Attractiveness Index
  • 4.3 Monoclonal Antibody Discovery & Analysis Market by Business Type, 2022-2032 (US$ mn)
  • 4.4 Monoclonal Antibody Discovery & Analysis Market by Region, 2022-2032 (US$ mn)
  • 4.5 Instruments Manufacturing
  • 4.6 Services & Solutions
    • 4.6.1 Services
    • 4.6.2 Solutions
  • 4.7 Ancillary kits

5 Monoclonal Antibody Discovery & Analysis Market Analysis by Application

  • 5.1 Key Findings
  • 5.2 Application Segment: Market Attractiveness Index
  • 5.3 Monoclonal Antibody Discovery & Analysis Market by Application, 2022-2032 (US$ mn)
  • 5.4 Monoclonal Antibody Discovery & Analysis Market by Region, 2022-2032 (US$ mn)
  • 5.5 Therapeutic Antibody Discovery
    • 5.5.1 Transgenic Animal Leveraging Transgenic Animal Platforms for Antibody Discovery
    • 5.5.2 Surrogate Antibodies
    • 5.5.3 Drug Development
    • 5.5.4 CAR-T Antibody Development
  • 5.6 Critical Reagent Antibody Discovery
    • 5.6.1 Anti-Idiotype Antibodies
    • 5.6.2 Reagents and Tests for Immunogenicity and ADA
    • 5.6.3 Antibodies and Assays for PK/PD/ADA
    • 5.6.4 Studies for Potency
  • 5.7 Biomarker and Diagnostic Antibody Discovery
  • 5.8 Research Antibody Discovery

6 Monoclonal Antibody Discovery & Analysis Market Analysis by Platform

  • 6.1 Key Findings
  • 6.2 Platform Segment: Market Attractiveness Index
  • 6.3 Monoclonal Antibody Discovery & Analysis Market by Platform, 2022-2032 (US$ mn)
  • 6.4 Monoclonal Antibody Discovery & Analysis Market by Region, 2022-2032 (US$ mn)
  • 6.5 Hybridoma
  • 6.6 Humanization
  • 6.7 Phage Display
  • 6.8 Yeast display
  • 6.9 Transgenic Rodents

7 Monoclonal Antibody Discovery & Analysis Market Analysis by Type

  • 7.1 Key Findings
  • 7.2 Type Segment: Market Attractiveness Index
  • 7.3 Type Segment Market Attractiveness Index
  • 7.4 Monoclonal Antibody Discovery & Analysis Market by Type, 2022-2032 (US$ mn)
  • 7.5 Monoclonal Antibody Discovery & Analysis Market by Region, 2022-2032 (US$ mn)
  • 7.6 Antigen Development
  • 7.7 Monoclonal Antibody Discovery
  • 7.8 Monoclonal Antibody Manufacturing
  • 7.9 Polyclonal Antibodies
  • 7.10 Label-Free Kinetics Analysis
  • 7.11 Cell Banking

8 Monoclonal Antibody Discovery & Analysis Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
  • 8.3 Monoclonal Antibody Discovery & Analysis Market Forecast, 2022-2032 (US$ mn)
  • 8.4 Monoclonal Antibody Discovery & Analysis Market by Region
  • 8.5 Monoclonal Antibody Discovery & Analysis Market by Business Type
  • 8.6 Monoclonal Antibody Discovery & Analysis Market by Application
  • 8.7 Monoclonal Antibody Discovery & Analysis Market by Platform
  • 8.8 Monoclonal Antibody Discovery & Analysis Market by Type

9 North America Monoclonal Antibody Discovery & Analysis Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
  • 9.3 North America Monoclonal Antibodies Market by Value, 2022-2032 (US$ Mn)
  • 9.4 Market Size Estimation and Forecast by Country
  • 9.5 Market Size Estimation and Forecast by Business Type
  • 9.6 Market Size Estimation and Forecast by Application
  • 9.7 Market Size Estimation and Forecast by Platform
  • 9.8 Market Size Estimation and Forecast by Type
  • 9.9 U.S. Market Analysis
  • 9.10 Canada Market Analysis

10 Europe Monoclonal Antibody Discovery & Analysis Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
  • 10.3 Europe Monoclonal Antibodies Market by Value, 2022-2032 (US$ mn)
  • 10.4 Market Size Estimation and Forecast by Country
  • 10.5 Market Size Estimation and Forecast by Business Type
  • 10.6 Market Size Estimation and Forecast by Application
  • 10.7 Market Size Estimation and Forecast by Platform
  • 10.8 Market Size Estimation and Forecast by Type
  • 10.9 Germany Market Analysis
  • 10.10 UK Market Analysis
  • 10.11 France Market Analysis
  • 10.12 Italy Market Analysis
  • 10.13 Spain Market Analysis
  • 10.14 Rest of Europe Market Analysis

11 Asia-Pacific Monoclonal Antibody Discovery & Analysis Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia-Pacific Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
  • 11.3 Asia-Pacific Monoclonal Antibodies Market by Value, 2022-2032 (US$ mn)
  • 11.4 Market Size Estimation and Forecast by Country
  • 11.5 Market Size Estimation and Forecast by Business Type
  • 11.6 Market Size Estimation and Forecast by Application
  • 11.7 Market Size Estimation and Forecast by Platform
  • 11.8 Market Size Estimation and Forecast by Type
  • 11.9 China Market Analysis
  • 11.10 India Market Analysis
  • 11.11 Japan Market Analysis
  • 11.12 South Korea Market Analysis
  • 11.13 Australia Market Analysis
  • 11.14 Rest of Asia-Pacific Market Analysis

12 Middle East and Africa Monoclonal Antibody Discovery & Analysis Market Analysis

  • 12.1 Key Findings
  • 12.2 Middle East and Africa Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
  • 12.3 Middle East and Africa Monoclonal Antibodies Market by Value, 2022-2032 (US$ Mn)
  • 12.4 Market Size Estimation and Forecast by Country
  • 12.5 Market Size Estimation and Forecast by Business Type
  • 12.6 Market Size Estimation and Forecast by Application
  • 12.7 Market Size Estimation and Forecast by Platform
  • 12.8 Market Size Estimation and Forecast by Type
  • 12.9 South Africa Market Analysis
  • 12.10 Saudi Arabia Market Analysis
  • 12.11 Turkey Market Analysis
  • 12.12 Rest of Middle East and Africa Market Analysis

13 Latin America Monoclonal Antibody Discovery & Analysis Market Analysis

  • 13.1 Key Findings
  • 13.2 Latin America Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
  • 13.3 Latin America Monoclonal Antibodies Market by Value, 2022-2032 (US$ mn)
  • 13.4 Market Size Estimation and Forecast by Country
  • 13.5 Market Size Estimation and Forecast by Business Type
  • 13.6 Market Size Estimation and Forecast by Application
  • 13.7 Market Size Estimation and Forecast by Platform
  • 13.8 Market Size Estimation and Forecast by Type
  • 13.9 Brazil Market Analysis
  • 13.10 Mexico Market Analysis
  • 13.11 Rest of Latin America Market Analysis

14 Competitive Landscape

  • 14.1 Company Share Analysis
  • 14.2 Key Business Strategy Analysis- Acquisition
  • 14.3 Key Business Strategy Analysis- Agreement
  • 14.4 Key Business Strategy Analysis- Alliance
  • 14.5 Key Business Strategy Analysis- Collaboration
  • 14.6 Key Business Strategy Analysis- Expansion
  • 14.7 Key Business Strategy Analysis- Joint Venture
  • 14.8 Key Business Strategy Analysis- New Product Launch
  • 14.9 Key Business Strategy Analysis- Partnership

15 Company Profiles

  • 15.1 AbbVie Inc.
    • 15.1.1 Company Snapshot
    • 15.1.2 Company Overview
    • 15.1.3 Financial Analysis
      • 15.1.3.1 Net Revenue, 2017-2021
      • 15.1.3.2 Gross Profit, 2017-2021
      • 15.1.3.3 R&D Expenses, 2017-2021
      • 15.1.3.4 Regional Revenue Share
    • 15.1.4 Product Benchmarking
    • 15.1.5 Strategic Outlook
  • 15.2 Amgen Inc.
    • 15.2.1 Company Snapshot
    • 15.2.2 Company Overview
    • 15.2.3 Financial Analysis
      • 15.2.3.1 Net Revenue, 2017-2021
      • 15.2.3.2 Gross Profit, 2017-2021
      • 15.2.3.3 R&D Expenses, 2017-2021
    • 15.2.4 Product Benchmarking
    • 15.2.5 Strategic Outlook
  • 15.3 Amneal Pharmaceutical LLC
    • 15.3.1 Company Snapshot
    • 15.3.2 Company Overview
    • 15.3.3 Financial Analysis
      • 15.3.3.1 Net Revenue, 2017-2021
      • 15.3.3.2 R&D Expenses, 2017-2021
    • 15.3.4 Strategic Outlook
  • 15.4 AstraZeneca
    • 15.4.1 Company Snapshot
    • 15.4.2 Company Overview
    • 15.4.3 Financial Analysis
      • 15.4.3.1 Net Revenue, 2017-2021
      • 15.4.3.2 R&D Expenses, 2017-2021
      • 15.4.3.3 Regional Revenue Share, 2021 (%)
    • 15.4.4 Product Benchmarking
    • 15.4.5 Strategic Outlook
  • 15.5 Bayer AG
    • 15.5.1 Company Snapshot
    • 15.5.2 Company Overview
    • 15.5.3 Financial Analysis
      • 15.5.3.1 Net Revenue, 2017-2021
      • 15.5.3.2 R&D Expenses, 2017-2021
      • 15.5.3.3 Regional Revenue Share, 2021 (%)
    • 15.5.4 Strategic Outlook
  • 15.6 BIOGEN
    • 15.6.1 Company Snapshot
    • 15.6.2 Company Overview
    • 15.6.3 Financial Analysis
      • 15.6.3.1 Net Revenue, 2017-2021
      • 15.6.3.2 R&D Expenses, 2017-2021
      • 15.6.3.3 Regional Revenue Share, 2021 (%)
    • 15.6.4 Product Benchmarking
    • 15.6.5 Strategic Outlook
  • 15.7 Bristol- Myers Squibb company
    • 15.7.1 Company Snapshot
    • 15.7.2 Company Overview
    • 15.7.3 Financial Analysis
      • 15.7.3.1 Net Revenue, 2017-2021
      • 15.7.3.2 R&D Expenses, 2017-2021
      • 15.7.3.3 Regional Revenue Share, 2021 (%)
    • 15.7.4 Product Benchmarking
    • 15.7.5 Strategic Outlook
  • 15.8 Eisai Co.Ltd
    • 15.8.1 Company Snapshot
    • 15.8.2 Company Overview
    • 15.8.3 Financial Analysis
      • 15.8.3.1 Net Revenue, 2017-2021
      • 15.8.3.2 R&D Expenses, 2017-2021
    • 15.8.4 Product Benchmarking
    • 15.8.5 Strategic Outlook
  • 15.9 Eli Lilly and Company
    • 15.9.1 Company Snapshot
    • 15.9.2 Company Overview
    • 15.9.3 Financial Analysis
      • 15.9.3.1 Net Revenue, 2017-2021
      • 15.9.3.2 R&D Expenses, 2017-2021
      • 15.9.3.3 Regional Revenue Share, 2021 (%)
    • 15.9.4 Product Benchmarking
    • 15.9.5 Strategic Outlook
  • 15.10 F. Hoffman-La Roche Ltd.
    • 15.10.1 Company Snapshot
    • 15.10.2 Company Overview
    • 15.10.3 Financial Analysis
      • 15.10.3.1 Net Revenue, 2017-2021
      • 15.10.3.2 R&D Expenses, 2017-2021
      • 15.10.3.3 Regional Revenue Share, 2021 (%)
    • 15.10.4 Product Benchmarking
    • 15.10.5 Strategic Outlook
  • 15.11 GlaxoSmithKline plc
    • 15.11.1 Company Snapshot
    • 15.11.2 Company Overview
    • 15.11.3 Financial Analysis
      • 15.11.3.1 Net Revenue, 2018-2021
      • 15.11.3.2 R&D Expenses, 2017-2021
      • 15.11.3.3 Regional Revenue Share
    • 15.11.4 Product Benchmarking
    • 15.11.5 Strategic Outlook
  • 15.12 Johnson & Johnson Ltd
    • 15.12.1 Company Snapshot
    • 15.12.2 Company Overview
    • 15.12.3 Financial Analysis
      • 15.12.3.1 Net Revenue, 2017-2021
      • 15.12.3.2 R&D Expenses, 2017-2021
      • 15.12.3.3 Regional Revenue Share, 2021 (%)
    • 15.12.4 Strategic Outlook
  • 15.13 Lupin Limited
    • 15.13.1 Company Snapshot
    • 15.13.2 Company Overview
    • 15.13.3 Product Benchmarking
    • 15.13.4 Strategic Outlook
  • 15.14 Viatris Inc.
    • 15.14.1 Company Snapshot
    • 15.14.2 Company Overview
    • 15.14.3 Financial Analysis
      • 15.14.3.1 Net Revenue, 2017-2021
      • 15.14.3.2 R&D Expenses, 2017-2021
    • 15.14.4 Product Benchmarking
    • 15.14.5 Strategic Outlook
  • 15.15 Novartis AG
    • 15.15.1 Company Snapshot
    • 15.15.2 Company Overview
    • 15.15.3 Financial Analysis
      • 15.15.3.1 Net Revenue, 2017-2021
      • 15.15.3.2 R&D Expenses, 2017-2021
      • 15.15.3.3 Regional Revenue Share, 2021 (%)
    • 15.15.4 Product Benchmarking
    • 15.15.5 Strategic Outlook
  • 15.16 Pfizer Inc.
    • 15.16.1 Company Snapshot
    • 15.16.2 Company Overview
    • 15.16.3 Financial Analysis
      • 15.16.3.1 Net Revenue, 2017-2021
      • 15.16.3.2 Regional Revenue Share, 2021 (%)
    • 15.16.4 Strategic Outlook
  • 15.17 Regeneron Pharmaceuticals Inc
    • 15.17.1 Company Snapshot
    • 15.17.2 Company Overview
    • 15.17.3 Financial Analysis
      • 15.17.3.1 Net Revenue, 2017-2021
      • 15.17.3.2 R&D Expenses, 2017-2021
    • 15.17.4 Product Benchmarking
    • 15.17.5 Strategic Outlook
  • 15.18 Sanofi S.A.
    • 15.18.1 Company Snapshot
    • 15.18.2 Company Overview
    • 15.18.3 Financial Analysis
      • 15.18.3.1 Net Revenue, 2017-2021
      • 15.18.3.2 R&D Expenses, 2017-2021
      • 15.18.3.3 Regional Revenue Share, 2021 (%)
    • 15.18.4 Product Benchmarking
    • 15.18.5 Strategic Outlook
  • 15.19 Teva Pharmaceutical Industries Ltd.
    • 15.19.1 Company Snapshot
    • 15.19.2 Company Overview
    • 15.19.3 Financial Analysis
      • 15.19.3.1 Net Revenue, 2017-2021
      • 15.19.3.2 R&D Expenses, 2017-2021
      • 15.19.3.3 Regional Revenue Share, 2021 (%)
    • 15.19.4 Strategic Outlook
  • 15.20 Zydus Lifesciences Limited
    • 15.20.1 Company Snapshot
    • 15.20.2 Company Overview
    • 15.20.3 Product Benchmarking
    • 15.20.4 Strategic Outlook

16 Conclusion and Recommendations

  • 16.1 Concluding Remarks from
  • 16.2 Recommendations for Market Players